Sponsor: Kangpu Biopharmaceuticals, Ltd.
KPG-121-101: A study using KPG-121 plus enzalutamide for patients with metastatic castration resistant prostate cancer whose PSA has failed, after 3 months, to respond to treatment with enzalutamide alone.
Call us (855) 528-7322
